Protara Therapeutics (NASDAQ:TARA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Protara Therapeutics (NASDAQ:TARA) from a strong sell rating to a sell rating in a research note released on Saturday,Wall Street Zen reports.

A number of other brokerages have also commented on TARA. HC Wainwright reiterated a “buy” rating on shares of Protara Therapeutics in a report on Wednesday, May 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Protara Therapeutics in a report on Friday, July 17th. UBS Group restated a “buy” rating on shares of Protara Therapeutics in a research report on Wednesday, May 20th. JPMorgan Chase & Co. dropped their price target on shares of Protara Therapeutics from $27.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, May 14th. Finally, Oppenheimer upped their price objective on shares of Protara Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a report on Wednesday, May 20th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $26.25.

Protara Therapeutics Stock Performance

TARA opened at $3.94 on Friday. Protara Therapeutics has a 1 year low of $3.02 and a 1 year high of $7.82. The firm has a 50 day moving average price of $4.01 and a 200 day moving average price of $4.69. The company has a market cap of $232.85 million, a PE ratio of -2.92 and a beta of 1.49.

Protara Therapeutics (NASDAQ:TARA) last issued its earnings results on Tuesday, August 11th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.03). On average, sell-side analysts predict that Protara Therapeutics will post -1.48 earnings per share for the current year.

Hedge Funds Weigh In On Protara Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of TARA. Corient Private Wealth LP purchased a new position in Protara Therapeutics during the second quarter valued at approximately $41,000. JPMorgan Chase & Co. acquired a new position in Protara Therapeutics during the second quarter worth $46,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Protara Therapeutics in the 2nd quarter worth approximately $53,000. Persistent Asset Partners Ltd acquired a new stake in shares of Protara Therapeutics in the fourth quarter worth $57,000. Finally, AXQ Capital LP acquired a new position in Protara Therapeutics during the 4th quarter worth $58,000. Hedge funds and other institutional investors own 38.13% of the company’s stock.

About Protara Therapeutics

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.